EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NFL Biosciences's enterprise value is €17.87 Mil.
NFL Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-4.05 Mil. Therefore, NFL Biosciences's EV-to-EBITDA for today is -4.41.
The historical rank and industry rank for NFL Biosciences's EV-to-EBITDA or its related term are showing as below:
XPAR:ALNFL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.04 Med: 0 Max: 0
Current: -4.42
XPAR:ALNFL's EV-to-EBITDA is ranked worse than 100% of 457
companies
in the Biotechnology industry
Industry Median: 9.79
vs XPAR:ALNFL: -4.42
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
NFL Biosciences EV-to-EBITDA Historical Data
The historical data trend for NFL Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of NFL Biosciences's EV-to-EBITDA
For the Biotechnology subindustry, NFL Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NFL Biosciences's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NFL Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NFL Biosciences's EV-to-EBITDA falls into.
NFL Biosciences's current Enterprise Value is €17.87 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NFL Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-4.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
NFL Biosciences's PE Ratio for today is calculated as:
NFL Biosciences's share price for today is €2.115.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NFL Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.479.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of NFL Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XPAR:ALNFL has been successfully added to your